Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.43 |
| ▸ | SHBG | P04278 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28591512 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL11440912 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL10929841 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL30271501 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL16110550 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL11440474 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL16319347 | 1.00 | EPHX1 (0.43) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL5824287 | 0.98 | EPHX1 (0.44) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| SCHEMBL28026127 | 0.98 | EPHX1 (0.39) | EPHX1SHBGCYP1A2SIGMAR1TSHR | |
| Cyanide SCHEMBL27483757 | 0.92 | EPHX1 (0.40) | EPHX1SHBGCYP1A2SIGMAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511862-A | Improved process for the preparation of copolymer-1 | MOMENTA PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | CN | claimed |
| EP-2046817-A1 | IMPROVED PROCESS FOR THE PREPARATION OF COPOLYMER-1 | Momenta Pharmaceuticals, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080021192-A1 | PROCESS FOR THE PREPARATION OF COPOLYMER-1 | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| WO-2008006026-A1 | IMPROVED PROCESS FOR THE PREPARATION OF COPOLYMER-1 | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| EP-2675824-B1 | COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF | USV PRIVATE LTD (IN) | 2017-09-27 | — | — | EP | disclosed |
| US-9029507-B2 | Copolymer-1, process for preparation and analytical methods thereof | USV LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| EP-2675824-A2 | COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF | USV Limited (IN) | 2013-12-25 | — | — | EP | disclosed |
| US-20130323771-A1 | COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF | USV LIMITED (IN) | 2013-12-05 | — | — | US | disclosed |
| US-20130281663-A1 | PREPARATION OF POLYPEPTIDES AND SALTS THEREOF | DR. REDDY'S LABORATORIES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2563804-A2 | PREPARATION OF POLYPEPTIDES AND SALTS THEREOF | Dr. Reddy's Laboratories Ltd. (IN) | 2013-03-06 | — | — | EP | disclosed |
| CN-102844325-A | Preparation of polypeptides and salts thereof | REDDYS LAB LTD DR | 2012-12-26 | — | — | CN | disclosed |
| WO-2012123959-A2 | COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF | USV LIMITED (IN) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012106584-A2 | PITAVASTATIN SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-08-09 | — | — | WO | disclosed |
| WO-2011139752-A2 | PREPARATION OF POLYPEPTIDES AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-11-10 | — | — | WO | disclosed |
| EP-2143728-A1 | Improved process for the preparation of copolymer-1 | Momenta Pharmaceuticals, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2046817-B1 | IMPROVED PROCESS FOR THE PREPARATION OF COPOLYMER-1 | MOMENTA PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | EP | disclosed |
| CN-101511862-A | Improved process for the preparation of copolymer-1 | MOMENTA PHARMACEUTICALS INC (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046817-A1 | IMPROVED PROCESS FOR THE PREPARATION OF COPOLYMER-1 | Momenta Pharmaceuticals, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080021192-A1 | PROCESS FOR THE PREPARATION OF COPOLYMER-1 | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2008006026-A1 | IMPROVED PROCESS FOR THE PREPARATION OF COPOLYMER-1 | MOMENTA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323771-A1 | COPOLYMER-1, PROCESS FOR PREPARATION AND ANALYTICAL METHODS THEREOF | NGLY1, PSMA1, IAPP | EPHX1 2523/4885SHBG 355/4885CYP1A2 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.